secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibikase Therapeutics, Inc. (IKT)
CIK:        0001750149
Form:       8-K
Filed at:   2025-04-14T23:59:59+00:00
Accession:  0001193125-25-079656
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibikase Therapeutics appoints David McIntyre as CFO as Garth Lees-Rolfe resigns
--------------------------------------------------------------------------------

- Garth Lees-Rolfe resigned as CFO effective April 11, 2025; not due to any dispute with the Company.
- David McIntyre appointed CFO effective April 14, 2025; previously CFO of Anthos Therapeutics and partner at Apple Tree Partners.
- McIntyre receives $485,000 base salary, 45% target bonus, and 3,142,967 stock options.
- Lees-Rolfe to consult through Aug 15, 2025 at $33,333/month; options continue vesting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750149/000119312525079656/0001193125-25-079656-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750149/000119312525079656/d857709d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-079656

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer